Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Barclays Maintains Overweight on Certara, Lowers Price Target to $21

Barclays Maintains Overweight on Certara, Lowers Price Target to $21

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $24 to $21.

byBenzinga Newsdesk

August 17, 2022

1 minute read

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $24 to $21.

Barclays Maintains Equal-Weight on Green Dot, Lowers Price Target to $19

By Benzinga Newsdesk

February 27, 7:39 AM

Barclays analyst Ramsey El-Assal maintains Green Dot (NYSE:GDOT) with a Equal-Weight and lowers the price target from $21 to $19.

GDOT

News

Telenav Picks Iteris’ ClearData Solution To Enhance Navigation Applications

By Benzinga Newsdesk

June 6, 8:35 AM

Telenav, Inc. to leverage Iteris' enhanced mobility data output, broadening Iteris' data usage in the enterprise market and enhancing Telenav's navigationIteris, Inc. (NASDAQ:ITI), the world's trusted technology

ITI

Credit Suisse Upgrades Esperion Therapeutics to Neutral, Raises Price Target to $7

By Benzinga Newsdesk

March 7, 6:08 AM

Credit Suisse analyst Judah Frommer upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underperform to Neutral and raises the price target from $6.5 to $7.

ESPR